Gabriel Vargas has been appointed chief medical officer of San Mateo, CA-based CuraSen Therapeutics. Vargas was most recently executive medical director, digital health and neuroscience therapeutic area head for early development at Amgen (NASDAQ: [[ticker:AMGN]]). Last month, CuraSen closed a $54 million Series A round of financing to support its development of small molecule drugs for neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
